Compare HTBK & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | CMPX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 752.4M |
| IPO Year | 1998 | N/A |
| Metric | HTBK | CMPX |
|---|---|---|
| Price | $11.41 | $5.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $11.88 | ★ $13.44 |
| AVG Volume (30 Days) | 366.9K | ★ 2.2M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $187,676,000.00 | N/A |
| Revenue This Year | $13.16 | N/A |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | $16.31 | ★ N/A |
| Revenue Growth | ★ 10.94 | N/A |
| 52 Week Low | $8.09 | $1.33 |
| 52 Week High | $11.44 | $5.86 |
| Indicator | HTBK | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 68.98 | 67.47 |
| Support Level | $11.06 | $5.13 |
| Resistance Level | $11.48 | $5.86 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 94.74 | 72.12 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.